Conmed Stock Performance
| CNMD Stock | USD 72.61 0.03 0.04% |
The firm shows a Beta (market volatility) of 0.44, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CONMED's returns are expected to increase less than the market. However, during the bear market, the loss of holding CONMED is expected to be smaller as well. CONMED has an expected return of -0.33%. Please make sure to confirm CONMED skewness, and the relationship between the treynor ratio and daily balance of power , to decide if CONMED performance from the past will be repeated in the future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days CONMED has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's primary indicators remain rather sound which may send shares a bit higher in May 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.4 | Five Day Return (5.98) | Year To Date Return (33.78) | Ten Year Return 55.27 | All Time Return 21.4 K |
Forward Dividend Yield 0.011 | Payout Ratio 0.2319 | Last Split Factor 3:2 | Forward Dividend Rate 0.8 | Dividend Date 2024-04-05 |
1 | Pulling back 9.6 percent this week, CONMEDs NYSECNMD five-year decline in earnings may be coming into investors focus | 01/29/2024 |
2 | Earnings call CONMED posts record revenue, optimistic about 2024 growth | 02/01/2024 |
3 | CONMED declares 0.20 dividend | 02/29/2024 |
4 | Payment of 273 shares by Mark Tryniski of CONMED subject to Rule 16b-3 | 03/01/2024 |
5 | Disposition of 25000 shares by Heather Cohen of CONMED at 78.76 subject to Rule 16b-3 | 03/08/2024 |
6 | Global Waterjet Cutting Machines Market Size is projected to reach USD 1,340.60 million by 2031, growing at a CAGR of 3.7 percent Straits Research | 03/14/2024 |
7 | Earnings growth of 23 percent over 3 years hasnt been enough to translate into positive returns for CONMED shareholders | 03/19/2024 |
8 | Public Employees Retirement System of Ohio Grows Position in CONMED Co. - Defense World | 03/22/2024 |
9 | CONMED Co. Receives Consensus Recommendation of Moderate Buy from Brokerages - Defense World | 03/27/2024 |
10 | Minimally Invasive Surgery Market is Expected to Reach 74.6 billion MarketsandMarkets | 04/01/2024 |
11 | Fifth Third Bancorp Raises Stock Position in CONMED Co. - Defense World | 04/04/2024 |
| CONMED dividend paid on 5th of April 2024 | 04/05/2024 |
12 | Should You Invest in CONMED | 04/10/2024 |
13 | Disposition of 8500 shares by John Ferrell of CONMED at 144.55 subject to Rule 16b-3 | 04/12/2024 |
14 | Mutual of America Capital Management LLC Buys 3145 Shares of CONMED Co. - Defense World | 04/17/2024 |
| Begin Period Cash Flow | 28.9 M |
CONMED |
CONMED Relative Risk vs. Return Landscape
If you would invest 9,087 in CONMED on January 24, 2024 and sell it today you would lose (1,826) from holding CONMED or give up 20.09% of portfolio value over 90 days. CONMED is currently does not generate positive expected returns and assumes 2.651% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than CONMED, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CONMED Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CONMED's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CONMED, and traders can use it to determine the average amount a CONMED's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1227
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CNMD |
Estimated Market Risk
| 2.65 actual daily | 23 77% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average CONMED is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CONMED by adding CONMED to a well-diversified portfolio.
CONMED Fundamentals Growth
CONMED Stock prices reflect investors' perceptions of the future prospects and financial health of CONMED, and CONMED fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CONMED Stock performance.
| Return On Equity | 0.0816 | ||||
| Return On Asset | 0.0347 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 3.2 B | ||||
| Shares Outstanding | 30.79 M | ||||
| Price To Earning | 188.03 X | ||||
| Price To Book | 2.75 X | ||||
| Price To Sales | 1.84 X | ||||
| Revenue | 1.24 B | ||||
| Gross Profit | 575.75 M | ||||
| EBITDA | 182.19 M | ||||
| Net Income | 64.46 M | ||||
| Cash And Equivalents | 33.35 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 991.25 M | ||||
| Debt To Equity | 1.45 % | ||||
| Current Ratio | 2.75 X | ||||
| Book Value Per Share | 27.12 X | ||||
| Cash Flow From Operations | 125.35 M | ||||
| Earnings Per Share | 2.04 X | ||||
| Market Capitalization | 2.24 B | ||||
| Total Asset | 2.3 B | ||||
| Retained Earnings | 452.53 M | ||||
| Working Capital | 304.92 M | ||||
| Current Asset | 393.34 M | ||||
| Current Liabilities | 119.72 M | ||||
About CONMED Performance
To evaluate CONMED Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when CONMED generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare CONMED Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand CONMED market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents CONMED's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 194.33 | 136.76 | |
| Return On Tangible Assets | 0.08 | 0.07 | |
| Return On Capital Employed | 0.07 | 0.09 | |
| Return On Assets | 0.03 | 0.04 | |
| Return On Equity | 0.08 | 0.07 |
Things to note about CONMED performance evaluation
Checking the ongoing alerts about CONMED for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CONMED help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CONMED generated a negative expected return over the last 90 days | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| On 5th of April 2024 CONMED paid $ 0.2 per share dividend to its current shareholders | |
| Latest headline from news.google.com: Mutual of America Capital Management LLC Buys 3145 Shares of CONMED Co. - Defense World |
- Analyzing CONMED's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CONMED's stock is overvalued or undervalued compared to its peers.
- Examining CONMED's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CONMED's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CONMED's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CONMED's stock. These opinions can provide insight into CONMED's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CONMED. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade CONMED Stock refer to our How to Trade CONMED Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for CONMED Stock analysis
When running CONMED's price analysis, check to measure CONMED's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CONMED is operating at the current time. Most of CONMED's value examination focuses on studying past and present price action to predict the probability of CONMED's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CONMED's price. Additionally, you may evaluate how the addition of CONMED to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is CONMED's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CONMED. If investors know CONMED will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CONMED listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.213 | Dividend Share 0.8 | Earnings Share 2.04 | Revenue Per Share 40.588 | Quarterly Revenue Growth 0.304 |
The market value of CONMED is measured differently than its book value, which is the value of CONMED that is recorded on the company's balance sheet. Investors also form their own opinion of CONMED's value that differs from its market value or its book value, called intrinsic value, which is CONMED's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CONMED's market value can be influenced by many factors that don't directly affect CONMED's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CONMED's value and its price as these two are different measures arrived at by different means. Investors typically determine if CONMED is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CONMED's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.